Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: A nationwide propensity score-matched study

European Journal of Preventive Cardiology

Volumn 21, Issue 3, 2014, Pages 330-338

  Bang, Casper N ^a,b   Gislason, Gunnar H ^b   Greve, Anders M ^a,b   Torp Pedersen, Christian ^b   Køber, Lars ^a   Wachtell, Kristian ^a,b  

^a Rigshospitalet   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Inflammation; myocardial infarction; new onset atrial fibrillation; statins

Indexed keywords

ATORVASTATIN; C 10AA 01; C 10AA 03; C 10AA 05; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DENMARK; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; POPULATION; PRESCRIPTION; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RECOMMENDED DRUG DOSE;

INFLAMMATION; MYOCARDIAL INFARCTION; NEW-ONSET ATRIAL FIBRILLATION; STATINS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CHI-SQUARE DISTRIBUTION; COMORBIDITY; DENMARK; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; POLYPHARMACY; PRAVASTATIN; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PYRROLES; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896704933     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/2047487312462804     Document Type: Article

References (46)

1. Jabre P, Jouven X, Adnet F, et al. Atrial fibrillation and death after myocardial infarction: a community study. Circulation. 2011 ; 123: 2094-2100
2. Mehta RH, Dabbous OH, Granger CB, et al. Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. Am J Cardiol. 2003 ; 92: 1031-1036
3. Lubitz SA, Magnani JW, Ellinor PT, et al. Atrial fibrillation and death after myocardial infarction: risk marker or causal mediator?. Circulation. 2011 ; 123: 2063-2065
4. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011 ; 57: e101 - e198
5. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998 ; 279: 1643-1650
6. Kourliouros A, De SA, Roberts N, et al. Dose-related effect of statins on atrial fibrillation after cardiac surgery. Ann Thorac Surg. 2008 ; 85: 1515-1520
7. Danchin N, Fauchier L, Marijon E, et al. Impact of early statin therapy on development of atrial fibrillation at the acute stage of myocardial infarction: data from the FAST-MI register. Heart. 2010 ; 96: 1809-1814
8. Naji F, Suran D, Kanic V, et al. Comparison of atorvastatin and simvastatin in prevention of atrial fibrillation after successful cardioversion. Int Heart J. 2009 ; 50: 153-160
9. Bang CN, Greve AM, Abdulla J, et al. The preventive effect of statin therapy on new-onset and recurrent atrial fibrillation in patients not undergoing invasive cardiac interventions - a systematic review and meta-analysis. Int J cardiol.. :
10. Haywood LJ, Ford CE, Crow RS, et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol. 2009 ; 54: 2023-2031
11. Adabag AS, Nelson DB, Bloomfield HE. Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure. Am Heart J. 2007 ; 154: 1140-1145
12. Maggioni AP, Fabbri G, Lucci D, et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J. 2009 ; 30: 2327-2336
13. Madsen M, Davidsen M, Rasmussen S, et al. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol. 2003 ; 56: 124-130
14. Gislason GH, Abildstrom SZ, Rasmussen JN, et al. Nationwide trends in the prescription of beta-blockers and angiotensin-converting enzyme inhibitors after myocardial infarction in Denmark, 1995-2002. Scand Cardiovasc J. 2005 ; 39: 42-49
15. Frost L, Andersen LV, Vestergaard P, et al. Trend in mortality after stroke with atrial fibrillation. Am J Med. 2007 ; 120: 47-53
16. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007 ; 297: 177-186
17. Tu JV, Austin PC, Walld R, et al. Development and validation of the Ontario acute myocardial infarction mortality prediction rules. J Am Coll Cardiol. 2001 ; 37: 992-997
18. Rasmussen S, Zwisler AD, Abildstrom SZ, et al. Hospital variation in mortality after first acute myocardial infarction in Denmark from 1995 to 2002: lower short-term and 1-year mortality in high-volume and specialized hospitals. Med Care. 2005 ; 43: 970-978
19. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997 ; 127: 757-763
20. Zhang X, Zhang MJ. SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards models. Comput Methods Programs Biomed. 2011 ; 101: 87-93
21. Hod H, Lew AS, Keltai M, et al. Early atrial fibrillation during evolving myocardial infarction: a consequence of impaired left atrial perfusion. Circulation. 1987 ; 75: 146-150
22. Tjandrawidjaja MC, Fu Y, Kim DH, et al. Compromised atrial coronary anatomy is associated with atrial arrhythmias and atrioventricular block complicating acute myocardial infarction. J Electrocardiol. 2005 ; 38: 271-278
23. Lopes RD, Elliott LE, White HD, et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J. 2009 ; 30: 2019-2028
24. Guazzi M, Berti M, Belletti S, et al. Exercise metaboreflex activation and endothelial function impairment in atrial fibrillation. Am J Physiol Heart Circ Physiol. 2006 ; 291: H2396 - H2402
25. Takahashi N, Ishibashi Y, Shimada T, et al. Impaired exercise-induced vasodilatation in chronic atrial fibrillation-role of endothelium-derived nitric oxide. Circ J. 2002 ; 66: 583-588
26. Guazzi M, Belletti S, Lenatti L, et al. Effects of cardioversion of atrial fibrillation on endothelial function in hypertension or diabetes. Eur J Clin Invest. 2007 ; 37: 26-34
27. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005 ; 45: 89-118
28. Wassmann S, Faul A, Hennen B, et al. Rapid effect of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res. 2003 ; 93: e98 - e103
29. Skalidis EI, Zacharis EA, Tsetis DK, et al. Endothelial cell function during atrial fibrillation and after restoration of sinus rhythm. Am J Cardiol. 2007 ; 99: 1258-1262
30. Werba JP, Tremoli E, Massironi P, et al. Statins in coronary bypass surgery: rationale and clinical use. Ann Thorac Surg. 2003 ; 76: 2132-2140
31. Ikeda K, Takahashi T, Yamada H, et al. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study). Eur J Prev Cardiol 2012 (Epub ahead of print).
32. Ramani G, Zahid M, Good CB, et al. Comparison of frequency of new-onset atrial fibrillation or flutter in patients on statins versus not on statins presenting with suspected acute coronary syndrome. Am J Cardiol. 2007 ; 100: 404-405
33. Pena JM, MacFadyen J, Glynn RJ, et al. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J. 2012 ; 33: 531-537
34. Pritchett EL. Management of atrial fibrillation. N Engl J Med. 1992 ; 326: 1264-1271
35. Fang WT, Li HJ, Zhang H, et al. The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol 2012 (Epub ahead of print).
36. Rahimi K, Emberson J, McGale P, et al. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ. 2011 ; 342: d1250 - d1250
37. Turner NA, Midgley L, O'Regan DJ, et al. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol. 2007 ; 50: 458-461
38. Obama R, Ishida H, Takizawa S, et al. Direct inhibition by a statin of TNFalpha-induced leukocyte recruitment in rat pial venules - in vivo confocal microscopic study. Pathophysiology. 2004 ; 11: 121-128
39. Mithani S, Akbar MS, Johnson DJ, et al. Dose dependent effect of statins on postoperative atrial fibrillation after cardiac surgery among patients treated with beta blockers. J Cardiothorac Surg. 2009 ; 4: 61-61
40. Chen WT, Krishnan GM, Sood N, et al. Effect of statins on atrial fibrillation after cardiac surgery: a duration- and dose-response meta-analysis. J Thorac Cardiovasc Surg. 2010 ; 140: 364-372
41. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997 ; 96: 2455-2461
42. Annoura M, Ogawa M, Kumagai K, et al. Cholesterol paradox in patients with paroxysmal atrial fibrillation. Cardiology. 1999 ; 92: 21-27
43. Aubert RE, Yao J, Xia F, et al. Is there a relationship between early statin compliance and a reduction in healthcare utilization?. Am J Manag Care. 2010 ; 16: 459-466
44. Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006 ; 113: 2363-2372
45. Stewart S, Murphy NF, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart. 2004 ; 90: 286-292
46. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998 ; 17: 2265-2281